Publications by authors named "Teja Thorat"

12Publications

Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis.

J Pediatr 2019 12;215:164-171.e2

Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2019.08.038DOI Listing
December 2019

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.

J Manag Care Spec Pharm 2018 Jul;24(7):632-642

1 Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2018.24.7.632DOI Listing
July 2018

Patient Variability Seldom Assessed in Cost-effectiveness Studies.

Med Decis Making 2018 05 19;38(4):487-494. Epub 2018 Jan 19.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X17746989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882686PMC
May 2018

When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.

PLoS Med 2017 Oct 2;14(10):e1002397. Epub 2017 Oct 2.

Center for Health Policy and the Center for Primary Care and Outcomes Research, Stanford University, Stanford, California, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.1002397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624570PMC
October 2017

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.

Health Aff (Millwood) 2017 08;36(8):1408-1415

Peter J. Neumann is director of the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, and a professor of medicine in the School of Medicine, Tufts University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2016.1541DOI Listing
August 2017

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.

PLoS One 2016 22;11(12):e0168512. Epub 2016 Dec 22.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168512PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179084PMC
July 2017

Private payers disagree with Medicare over medical device coverage about half the time.

Health Aff (Millwood) 2015 Aug;34(8):1376-82

Peter J. Neumann is director of the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and a professor of medicine in the School of Medicine, Tufts University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2015.0133DOI Listing
August 2015

The State of Cost-Utility Analyses in Asia: A Systematic Review.

Value Health Reg Issues 2015 May 24;6:7-13. Epub 2015 Mar 24.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2015.02.001DOI Listing
May 2015

The changing face of the cost-utility literature, 1990-2012.

Value Health 2015 Mar 22;18(2):271-7. Epub 2015 Jan 22.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2014.12.002DOI Listing
March 2015

The lag from FDA approval to published cost-utility evidence.

Expert Rev Pharmacoecon Outcomes Res 2015 Jun 12;15(3):399-402. Epub 2015 Jan 12.

Tufts Medical Center, Center for the Evaluation of Value and Risk in Health, 800 Washington Street #63, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.2015.1001371DOI Listing
June 2015

Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs.

Health Aff (Millwood) 2014 Oct;33(10):1751-60

Peter J. Neumann is director of the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, and a professor of medicine in the School of Medicine at Tufts University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2014.0574DOI Listing
October 2014